"We had this crazy idea a few years ago, and we talked to a lot of people. Usually when we have these ideas, some people will say one of two things: 'That's absolutely brilliant, I'm in' or 'That's the stupidest idea I've ever heard.' Both are extremely validating for us."
"That's the promise of X-Men: the company develops therapies by studying the genes of medically pertinent outliers. To date, Variant has raised about $130 million from big names like SoftBank Vision Fund and General Catalyst—and, of course, Lux."
"There's also this perfect storm of what's going on in the market now that I think this is an advantaged investment strategy. Venture is in a pullback, Wolfe says, making this the ideal time to pursue a differentiated approach."
Collection
[
|
...
]